Skip to content

An evaluation of two eight-month regimens of chemotherapy for the treatment of newly diagnosed pulmonary tuberculosis

An evaluation of two eight-month regimens of chemotherapy for the treatment of newly diagnosed pulmonary tuberculosis: A multicentre, single-blinded, randomised controlled trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ISRCTN
Registry ID
ISRCTN19832141
Enrollment
1500
Registered
2010-04-15
Start date
1998-03-01
Completion date
Unknown
Last updated
2015-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Smear-positive pulmonary tuberculosis Infections and Infestations Respiratory tuberculosis, bacteriologically and histologically confirmed

Interventions

Participants from 8 sites with smear positive pulmonary tuberculosis who had never previously treated were randomly assigned from a table of random numbers to one of three treatment regimens: 1. Inte

Sponsors

International Union Against Tuberculosis and Lung Disease (France)
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Age 15 to 65 years 2. Two sputum specimens positive for acid-fast bacilli on direct smear microscopy 3. No previous anti-tuberculosis chemotherapy for more than one month 4. A specific home address readily accessible for visiting in case of a failure to attend 5. Informed consent given and agreed to participate in the study and to give a sample of blood, urine or saliva for HIV testing

Exclusion criteria

Exclusion criteria: 1. So ill they were thought unlikely to survive the initial weeks of treatment 2. Presence of extra-pulmonary tuberculosis 3. Concomitant diseases likely to prejudice the response to, or assessment of, treatment such as 3.1. Diabetes 3.2. Liver disease 3.3. Nephritis 3.4. Blood disorders 3.5. Epilepsy 3.6. Peripheral neuritis 4. Known to be pregnant 5. Suffering from a psychiatric illness or alcoholism

Design outcomes

Primary

MeasureTime frame
The proportion of patients with negative cultures at two months and the status of patients 12 months after completion of chemotherapy (i.e. at 18 or 20 months after start of chemotherapy depending on the regimen). The two-month culture result was chosen to compare the rate of sputum conversion of the three times weekly intensive phase with that of the daily intensive phase

Secondary

MeasureTime frame
The proportion of failures at the end of chemotherapy (at 6 or 8 months after start of chemotherapy) and the proportion patients with adverse events requiring stopping of their chemotherapy or an interruption of treatment for 7 days or more

Countries

Benin, China, Guinea, Mozambique, Nepal, Tanzania

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026